Silexion Therapeutics Corp
Silexion Therapeutics Corp
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||
Cash And Cash Equivalents At Carrying Value | 2 | 2 | 6 | 9 | 3 | 6 | 1 | 2 | 2 | |||||
Restricted Cash Current | - | - | - | - | - | - | - | - | 0 | |||||
Restricted Cash And Cash Equivalents At Carrying V… | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | |||||
Prepaid Expense Current | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | |||||
Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Assets Current | 4 | 4 | 7 | 11 | 5 | 8 | 2 | 3 | 2 | |||||
Assets Noncurrent | ||||||||||||||
Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Deposits Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | |||||
Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | |||||
Liabilities And Redeemabl… | ||||||||||||||
Assets | 4 | 5 | 7 | 12 | 6 | 8 | 3 | 3 | 2 | |||||
Liabilities Current | ||||||||||||||
Accounts Payable Trade Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | |||||
Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Employee Related Liabilities Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | |||||
Other Accounts Payable And Accrued Liabilities | - | - | 1 | 1 | 1 | 1 | 1 | 2 | 1 | |||||
Accounts Payable Other Current | 1 | 1 | - | - | - | - | - | - | - | |||||
Liabilities Current | 4 | 4 | 3 | 3 | 2 | 2 | 4 | 4 | 2 | |||||
Liabilities Noncurrent | ||||||||||||||
Other Liabilities Current | - | - | - | - | - | - | 0 | 0 | 0 | |||||
Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Liabilities Noncurrent | 0 | 0 | 2 | 2 | 4 | 3 | 3 | 4 | 0 | |||||
Temporary Equity Carrying… | ||||||||||||||
Liabilities | 4 | 4 | 5 | 5 | 6 | 6 | 7 | 8 | 2 | |||||
Stockholders Equity | ||||||||||||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital | 61 | 58 | 58 | 58 | 48 | 48 | 39 | 37 | 11 | |||||
Retained Earnings Accumulated Deficit | -61 | -58 | -55 | -51 | -47 | -45 | -43 | -42 | -30 | |||||
Stockholders Equity | 0 | 0 | 3 | 7 | 0 | 3 | -4 | -5 | -18 | |||||
Liabilities And Stockholders Equity | 4 | 5 | 7 | 12 | 6 | 8 | 3 | 3 | 3 | |||||
Related Party | - | 2 | 2 | -2 | 3 | 0 | 0 | -0 | 0 | |||||
Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | 0.01 | |||||
Convertible Preferred Stock Nonredeemable Or Redee… | - | - | - | - | - | - | 0 | 0 | 15 | |||||
Redeemable Noncontrolling Interest Equity Preferre… | - | - | - | - | - | - | 0 | 0 | 3 | |||||
Common Stock Par Or Stated Value Per Share | 0.135 | 0.014 | 0.013 | 0.014 | 0.014 | 0.001 | 0.013 | 0 | 0.01 | |||||
Common Stock Shares Authorized | 6 | 9 | 9 | 9 | 1 | 22 | 1,481 | 200 | 3 | |||||
Preferred Stock Redemption Amount | - | - | - | - | - | - | 0 | 0 | 18 | |||||
Common Stock Shares Issued | 1 | 0 | 0 | 0 | 0 | 0 | 12 | 0 | 0 | |||||
Shares Outstanding | 1 | 0 | 0 | 0 | 0 | 0 | 12 | 0 | 0 | |||||
Convertible Series A Preferred Shares | - | - | - | - | - | - | 0 | 0 | 0 | |||||
Convertible Series A One Preferred Shares | - | - | - | - | - | - | 0 | 0 | 0 | |||||
Convertible Series A Two Preferred Shares | - | - | - | - | - | - | - | - | 0 | |||||
Convertible Series A2 Preferred Shares | - | - | - | - | - | - | 0 | 0 | - | |||||
Convertible Series A Three Preferred Shares | - | - | - | - | - | - | 0 | 0 | 0 | |||||
Convertible Series A Four Preferred Shares | - | - | - | - | - | - | 0 | 0 | 0 | |||||
Assets | ||||||||||||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 61.59% | -8.48% | -34.95% | - | - | - | - | - | - | - | - | - |
| 2025 | -2.47% | -16.39% | -36.22% | -1.38% | -45.79% | -54.29% | 3.78% | -35.40% | -37.11% | -32.69% | -66.35% | -70.06% |
| 2024 | - | - | - | -44.23% | -76.35% | -86.41% | 1127.68% | 859.82% | 748.21% | -32.40% | -21.20% | -24.32% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Silexion Therapeutics Corp (SLXN) — SEC Financial Statements & Analysis
Silexion Therapeutics Corp (SLXN) is a biological products, (no diagnostic substances) company, incorporated in E9. Silexion Therapeutics Corp trades on Nasdaq as: SLXN, SLXNW. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Silexion Therapeutics Corp reported a Debt-to-Equity ratio of 95.50x, a Price-to-Book (P/B) ratio of 39.84x (TTM), at a market cap of $1.75M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- 95.50x
- P/B TTM
- 39.84x
- Market Cap
- $1.75M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Silexion Therapeutics Corp in?
Silexion Therapeutics Corp (SLXN) operates in the Biological Products, (No Diagnostic Substances) industry.
What is SLXN's market cap?
Silexion Therapeutics Corp (SLXN) has a market capitalization of $1.75M as of 2026-06-30.
What is SLXN's P/E ratio?
Silexion Therapeutics Corp (SLXN)'s trailing twelve month P/E ratio is 0.13x as of 2026-06-30.
What exchange does SLXN trade on?
Silexion Therapeutics Corp (SLXN) trades on the Nasdaq.
Where is Silexion Therapeutics Corp incorporated?
Silexion Therapeutics Corp is incorporated in Cayman Islands.